Becton, Dickinson and Company (NYSE:BDX) Holdings Trimmed by First National Bank of Mount Dora Trust Investment Services

First National Bank of Mount Dora Trust Investment Services lowered its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 42.9% in the third quarter, HoldingsChannel reports. The institutional investor owned 3,870 shares of the medical instruments supplier’s stock after selling 2,911 shares during the period. First National Bank of Mount Dora Trust Investment Services’ holdings in Becton, Dickinson and Company were worth $933,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the stock. WR Wealth Planners LLC boosted its stake in shares of Becton, Dickinson and Company by 1.4% during the 2nd quarter. WR Wealth Planners LLC now owns 2,978 shares of the medical instruments supplier’s stock valued at $696,000 after buying an additional 42 shares during the period. Clear Creek Financial Management LLC lifted its stake in shares of Becton, Dickinson and Company by 5.1% in the 2nd quarter. Clear Creek Financial Management LLC now owns 900 shares of the medical instruments supplier’s stock valued at $210,000 after purchasing an additional 44 shares during the last quarter. Sound Income Strategies LLC raised its holdings in Becton, Dickinson and Company by 35.8% in the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after acquiring an additional 44 shares during the period. Central Pacific Bank Trust Division raised its holdings in Becton, Dickinson and Company by 22.5% in the 3rd quarter. Central Pacific Bank Trust Division now owns 245 shares of the medical instruments supplier’s stock worth $59,000 after acquiring an additional 45 shares during the period. Finally, Capital Advisors Ltd. LLC raised its holdings in Becton, Dickinson and Company by 3.6% in the 2nd quarter. Capital Advisors Ltd. LLC now owns 1,394 shares of the medical instruments supplier’s stock worth $326,000 after acquiring an additional 48 shares during the period. Institutional investors and hedge funds own 86.97% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on BDX. Raymond James dropped their target price on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a report on Friday, August 2nd. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Evercore ISI boosted their price objective on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Stifel Nicolaus boosted their price objective on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a report on Friday, July 26th. Finally, Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $255.00 to $275.00 in a report on Tuesday, October 1st. Nine analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $282.63.

Becton, Dickinson and Company Price Performance

NYSE BDX traded up $0.07 on Monday, reaching $235.31. The company’s stock had a trading volume of 331,553 shares, compared to its average volume of 1,366,898. The firm has a market cap of $68.01 billion, a PE ratio of 48.40, a price-to-earnings-growth ratio of 1.75 and a beta of 0.43. The business has a 50-day moving average price of $237.56 and a 200 day moving average price of $235.09. Becton, Dickinson and Company has a 52 week low of $218.75 and a 52 week high of $259.92. The company has a current ratio of 1.85, a quick ratio of 1.36 and a debt-to-equity ratio of 0.70.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share for the quarter, beating analysts’ consensus estimates of $3.31 by $0.19. The business had revenue of $4.99 billion for the quarter, compared to analysts’ expectations of $5.08 billion. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The firm’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.96 earnings per share. Sell-side analysts expect that Becton, Dickinson and Company will post 13.11 EPS for the current year.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.